Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Haabeth, Ole Audun Werner ^a   Lorvik, Kristina Berg ^a   Hammarström, Clara ^b   Donaldson, Ian M ^a   Haraldsen, Guttorm ^b   Bogen, Bjarne ^a   Corthay, Alexandre ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; ANGIOSTATIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; MACROPHAGE; MOUSE; MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; TH1 CELL; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; CYTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE MUTANT; MULTIPLE MYELOMA; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TH2 CELL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

MUS;

ANGIOSTATIC PROTEINS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMOKINE CXCL10; CHEMOKINE CXCL9; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-6; LYMPHOMA, B-CELL; MACROPHAGES; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASMS; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; TUMOR MICROENVIRONMENT;

EID: 79952712968     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1239     Document Type: Article

References (60)

1. Shankaran, V. et al IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410, 1107-1111 (2001). (Pubitemid 32391043)
2. Zhang, L. et al Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003). (Pubitemid 36077915)
3. Galon, J. et al Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006). (Pubitemid 44498003)
4. Voronov, E. et al IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad. Sci. USA 100, 2645-2650 (2003). (Pubitemid 36297552)
5. Konishi, N. et al Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology 68, 138-145 (2005). (Pubitemid 41158969)
6. Lin, W. W. & Karin, M. A cytokine-mediated link between innate immunity infammation, and cancer. J. Clin. Invest 117, 1175-1183 (2007). (Pubitemid 46718402)
7. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related infammation. Nature 454, 436-444 (2008).
8. Kim, S. et al Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106 (2009).
9. Park, E. J. et al Dietary and genetic obesity promote liver infammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
10. Levitsky H. I., Lazenby A., Hayashi, R. J. & Pardoll, D. M. In vivo priming of two distinct antitumor efector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215-1224 (1994). (Pubitemid 24091780)
11. Bogen, B. et al. Naive CD4+ T cells confer idiotype-specifc tumor resistance in the absence of antibodies. Eur. J. Immunol. 25, 3079-3086 (1995).
12. Kohrt, H. E. et al. Profle of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2, e284 (2005).
13. Nakamura, H. et al Immunologic parameters as signifcant prognostic factors in lung cancer. Lung Cancer 37, 161-169 (2002). (Pubitemid 34831808)
14. Unitt, E. et al Tumour lymphocytic infltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 45, 246-253 (2006).
15. Knutson, K. L., Disis, M. L. & Salazar, L. G. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol. Immunother 56, 271-285 (2007). (Pubitemid 46035899)
16. Bogen, B., Malissen, B. & Haas, W. Idiotope-specifc T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 16, 1373-1378 (1986). (Pubitemid 17206155)
17. Lauritzsen, G. F., Weiss, S., Dembic, Z. & Bogen, B. Naive idiotype-specifc CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad. Sci. USA 91, 5700-5704 (1994). (Pubitemid 24174396)
18. Corthay A. et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22, 371-383 (2005). (Pubitemid 40387478)
19. Kleinman, H. K. et al Basement membrane complexes with biological activity Biochemistry 25, 312-318 (1986). (Pubitemid 16053790)
20. Corthay A., Lundin, K. U., Lorvik, K. B., Hofgaard, P. O. & Bogen, B. Secretion of tumor-specifc antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res. 69, 5901-5907 (2009).
21. Weiss, S. & Bogen, B. MHC class II-restricted presentation of intracellular antigen. Cell 64, 767-776 (1991). (Pubitemid 121001164)
22. Dalton, D. K. et al Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259, 1739-1742 (1993). (Pubitemid 23114658)
23. Muranski, P. et al Tumor-specifc T17-polarized cells eradicate large established melanoma. Blood 112, 362-373 (2008).
24. Roder, J. & Duwe, A. Te beige mutation in the mouse selectively impairs natural killer cell function. Nature 278, 451-453 (1979). (Pubitemid 9130703)
25. Budhu, A. et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10, 99-111 (2006). (Pubitemid 44202603)
26. Finak, G. et al Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 14, 518-527 (2008). (Pubitemid 351655218)
27. Wetzler, M. et al Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 84, 3142-3147 (1994).
28. Vidal-Vanaclocha, F., Amezaga, C., Asumendi, A., Kaplanski, G. & Dinarello, C. A. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res. 54, 2667-2672 (1994). (Pubitemid 24173756)
29. Pelliniemi, T. T. et al Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85, 765-771 (1995).
30. Preti, H. A. et al Prognostic value of serum interleukin-6 in difuse large-cell lymphoma. Ann. Intern. Med. 127, 186-194 (1997). (Pubitemid 27332536)
31. Martin, F. et al Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 80-86 (1999). (Pubitemid 29097356)
32. Klintrup, K. et al Infammation and prognosis in colorectal cancer. Eur. J. Cancer 41, 2645-2654 (2005).
33. Lee, A. H. et al. Diferent patterns of infammation and prognosis in invasive carcinoma of the breast. Histopathology 48, 692-701 (2006).
34. Cai, T. et al Prognostic role of the tumor-associated tissue infammatory reaction in transitional bladder cell carcinoma. Oncol. Rep. 16, 329-334 (2006).
35. Von Stebut, E. et al Interleukin 1alpha promotes T1 diferentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J. Exp. Med. 198, 191-199 (2003). (Pubitemid 36992177)
36. Ben-Sasson, S. Z. et al IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and diferentiation. Proc. Natl Acad. Sci. USA 106, 7119-7124 (2009).
37. Philip, R. & Epstein, L. B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323, 86-89 (1986). (Pubitemid 16012356)
38. Martinon, F., Mayor, A. & Tschopp, J. Te infammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
39. Ghiringhelli, F. et al Activation of the NLRP3 infammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 15, 1170-1178 (2009).
40. Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1, 447-456 (1994).
41. Qin, Z. & Blankenstein, T. CD4+ T cell\mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12, 677-686 (2000).
42. Schreiber, R. D., Pace, J. L., Russell, S. W., Altman, A. & Katz, D. H. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J. Immunol. 131, 826-832 (1983). (Pubitemid 13077797)
43. Bonecchi, R. et al. Diferential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (T1s) and T2s. J. Exp. Med. 187, 129-134 (1998). (Pubitemid 28044828)
44. Nakanishi, Y., Lu, B., Gerard, C. & Iwasaki, A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462, 510-513 (2009).
45. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
46. Luster, A. D., Greenberg, S. M. & Leder, P. Te IP-10 chemokine binds to a specifc cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182, 219-231 (1995).
47. Angiolillo, A. L. et al Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182, 155-162 (1995).
48. Lasagni, L. et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197, 1537-1549 (2003). (Pubitemid 36682550)
49. Sgadari, C. et al. Interferon-inducible protein-10 identifed as a mediator of tumor necrosis in vivo. Proc. Natl Acad. Sci. USA 93, 13791-13796 (1996). (Pubitemid 26424199)
50. Arenberg, D. A. et al Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184, 981-992 (1996).
51. Sgadari, C. et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89, 2635-2643 (1997). (Pubitemid 27172547)
52. Carswell, E. A. et al An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad. Sci. USA 72, 3666-3670 (1975).
53. Cherix, S. et al Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable sof tissue sarcomas: long-term results on efcacy and limb salvage in a selected group of patients. J. Surg. Oncol. 98, 148-155 (2008).
54. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J. Clin. Oncol. 13, 688-696 (1995).
55. Kirkwood, J. M. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin Oncol. 14, 7-17 (1996). (Pubitemid 26019991)
56. Rohatiner, A. Z. et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. Oncol. 23, 2215-2223 (2005). (Pubitemid 46218713)
57. Spitler, L. E. et al Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin Oncol. 18, 1614-1621 (2000). (Pubitemid 30220539)
58. Cheever, M. A. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222, 357-368 (2008). (Pubitemid 351430366)
59. Fleischmann, W. R. Jr, Kleyn, K. M. & Baron, S. Potentiation of antitumor efect of virus-induced interferon by mouse immune interferon preparations. J. Natl Cancer Inst 65, 963-966 (1980). (Pubitemid 11215024)
60. Rosenberg, S. A., Schwarz, S. L. & Spiess, P. J. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infltrating lymphocytes. J. Natl Cancer Inst. 80, 1393-1397 (1988).